{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:44:53Z","timestamp":1783421093862,"version":"3.54.6"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Herzzentrum G\u00f6ttingen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Diagnosis of brain metastases (BM) has traditionally marked a turning point in treatment goals and prognosis of patients with breast cancer (BC). However, new systemic treatment options have both prevented the development and improved the prognosis of BC patients with BM. Stereotactic radiotherapy techniques (SRT) have widely replaced whole brain radiotherapy (WBRT) in patients with limited BM, yielding impressive survival at modest toxicity rates. However, based on established prognostic scores, many patients will not profit from modern SRT treatment concepts and, therefore, remain candidates for WBRT or best supportive care (BSC). Here, treatment decisions may be challenging. This study aims to describe clinical outcomes and explore potential prognostic factors in a single-center cohort of BC patients treated with WBRT comprising patients across the prognosis continuum reflecting everyday work routine. We retrospectively analyzed 108 patients diagnosed with BM who received WBRT between 2008 and 2020. The cohort included patients with a broad range of prognostic factors (\u2265 60 years old, Karnofsky Performance Status [KPS] \u2264 70, &gt;3 BM and a Graded Prognostic Assessment [GPA] score &lt; 1 [anticipated life expectancy of &lt; 4 months]), who were either treated with palliative WBRT alone or in case of focal symptoms attributed to individual location of metastasis with surgery, SRT, or WBRT + focal dose escalation (\u201cboost\u201d). Survival rates were estimated using the Kaplan\u2013Meier method, and factors potentially affecting outcome were statistically assessed by the log-rank test. Uni- and multivariable Cox regression was used in survival analysis to estimate hazard ratios and to evaluate the influence of various variables on survival time. For all statistical procedures SPSS software (v. 26) was used. Median survival after diagnosis of BM was 4 months (95% CI 3\u20135 months). The most relevant negative prognostic factor within the group of GPA-classifiers was KPS (\u2264 70), followed by the number of BM (&gt;3). Metastasectomy displayed significantly improved survival in univariable analysis (log rank\n                    <jats:italic>p<\/jats:italic>\n                    = 0.008; Cox-Regression\n                    <jats:italic>p<\/jats:italic>\n                    = 0.018), but did not elicit as predictive for OS in multivariable analysis (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.47). Furthermore, completion of the prescribed RT series had the strongest impact on OS in both univariable and multivariable Cox regression analyses (\n                    <jats:italic>p<\/jats:italic>\n                    &lt; 0.00001) while delivery of a radiation boost in addition to WBRT exerted no significant benefit (Cox regression\n                    <jats:italic>p<\/jats:italic>\n                    = 0.358). Despite the continuous development of effective treatment strategies for BM, BC patients who are ineligible for innovative treatment modalities show poor survival rates. Following prognostic assessment may help to make treatment decisions. KPS and number of BM may be most important in this context. In our retrospective cohort surgical removal of BM and completion of RT series were associated with improved prognosis, while focal radiation dose escalation in addition to WBRT was not.\n                  <\/jats:p>","DOI":"10.1007\/s10585-025-10376-9","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:16:50Z","timestamp":1761556610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Borderline decisions in brain-metastatic breast cancer: efficacy of multimodality treatments in breast cancer patients with very limited prognosis suffering from brain metastases"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6562-6616","authenticated-orcid":false,"given":"Stephanie","family":"Bendrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc Alexander Wilhelm","family":"Pietrkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus Anton","family":"Schirmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne Elisabeth","family":"Ammon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif Hendrik","family":"Dr\u00f6ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Anna","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Marie","family":"Zwerenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotta Friederike","family":"Pagel-Nozari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Rieken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Gallwas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Guhlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Donath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"10376_CR1","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.breast.2014.06.009","volume":"23","author":"C Aversa","year":"2014","unstructured":"Aversa C, Rossi V, Geuna E et al (2014) Metastatic breast cancer subtypes and central nervous system metastases. Breast 23:623\u2013628. https:\/\/doi.org\/10.1016\/j.breast.2014.06.009","journal-title":"Breast"},{"key":"10376_CR2","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/j.ijrobp.2011.02.027","volume":"82","author":"PW Sperduto","year":"2011","unstructured":"Sperduto PW, Kased N, Roberge D et al (2011) The effect of tumor subtype on survival and the graded prognostic assessment (GPA) for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys 82:2111\u20132117. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.02.027","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10376_CR3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/ijc.32767","volume":"147","author":"A Katalinic","year":"2020","unstructured":"Katalinic A, Eisemann N, Kraywinkel K et al (2020) Breast cancer incidence and mortality before and after implementation of the German mammography screening program. Int J Cancer 147:709\u2013718. https:\/\/doi.org\/10.1002\/ijc.32767","journal-title":"Int J Cancer"},{"key":"10376_CR4","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s10549-014-3242-x","volume":"149","author":"E Cho","year":"2015","unstructured":"Cho E, Rubinstein L, Stevenson P et al (2015) The use of stereotactic radiosurgery for brain metastases from breast cancer: who benefits most? Breast Cancer Res Treat 149:743\u2013749. https:\/\/doi.org\/10.1007\/s10549-014-3242-x","journal-title":"Breast Cancer Res Treat"},{"key":"10376_CR5","doi-asserted-by":"publisher","unstructured":"Almeida ND, Kuo C, Schrand TV et al (2024) Stereotactic radiosurgery for intracranial breast metastases: a systematic review and Meta-Analysis. Cancers (Basel) 16. https:\/\/doi.org\/10.3390\/cancers16203551","DOI":"10.3390\/cancers16203551"},{"key":"10376_CR6","doi-asserted-by":"publisher","first-page":"104433","DOI":"10.1016\/j.breast.2025.104433","volume":"81","author":"E Laakmann","year":"2025","unstructured":"Laakmann E, Schmidt M, L\u00fcbbe K et al (2025) Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases from a large registry of BMBC. Breast 81:104433. https:\/\/doi.org\/10.1016\/j.breast.2025.104433","journal-title":"Breast"},{"key":"10376_CR7","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/s0360-3016(96)00619-0","volume":"37","author":"L Gaspar","year":"1997","unstructured":"Gaspar L, Scott C, Rotman M et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745\u2013751. https:\/\/doi.org\/10.1016\/s0360-3016(96)00619-0","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10376_CR8","doi-asserted-by":"publisher","unstructured":"Agaronnik ND, Peters MLB, Iezzoni LI (2025) Exclusion of people from oncology clinical trials based on functional status. Clin Trials 17407745241304114. https:\/\/doi.org\/10.1177\/17407745241304114","DOI":"10.1177\/17407745241304114"},{"key":"10376_CR9","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/S0140-6736(16)30825-X","volume":"388","author":"P Mulvenna","year":"2016","unstructured":"Mulvenna P, Nankivell M, Barton R et al (2016) Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet 388:2004\u20132014. https:\/\/doi.org\/10.1016\/S0140-6736(16)30825-X","journal-title":"Lancet"},{"key":"10376_CR10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.5306\/wjco.v12.i3.164","volume":"12","author":"D O\u2019Reilly","year":"2021","unstructured":"O\u2019Reilly D, Sendi MA, Kelly CM (2021) Overview of recent advances in metastatic triple negative breast cancer. World J Clin Oncol 12:164\u2013182. https:\/\/doi.org\/10.5306\/wjco.v12.i3.164","journal-title":"World J Clin Oncol"},{"key":"10376_CR11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.2147\/OTT.S293685","volume":"14","author":"Y Lv","year":"2021","unstructured":"Lv Y, Ma X, Du Y et al (2021) Understanding patterns of brain metastasis in Triple-Negative breast cancer and exploring potential therapeutic targets. Onco Targets Ther 14:589\u2013607. https:\/\/doi.org\/10.2147\/OTT.S293685","journal-title":"Onco Targets Ther"},{"key":"10376_CR12","doi-asserted-by":"publisher","first-page":"vdz017","DOI":"10.1093\/noajnl\/vdz017","volume":"1","author":"P Kancharla","year":"2019","unstructured":"Kancharla P, Ivanov A, Chan S et al (2019) The effect of brain metastasis location on clinical outcomes: A review of the literature. Neurooncol Adv 1:vdz017. https:\/\/doi.org\/10.1093\/noajnl\/vdz017","journal-title":"Neurooncol Adv"},{"key":"10376_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4048\/jbc.2015.18.1.29","volume":"18","author":"JU Chong","year":"2015","unstructured":"Chong JU, Ahn SG, Lee HM et al (2015) Local control of brain metastasis: treatment outcome of focal brain treatments in relation to subtypes. J Breast Cancer 18:29\u201335. https:\/\/doi.org\/10.4048\/jbc.2015.18.1.29","journal-title":"J Breast Cancer"},{"key":"10376_CR14","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1001\/jama.280.17.1485","volume":"280","author":"RA Patchell","year":"1998","unstructured":"Patchell RA, Tibbs PA, Regine WF et al (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280:1485\u20131489. https:\/\/doi.org\/10.1001\/jama.280.17.1485","journal-title":"JAMA"},{"key":"10376_CR15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/ana.410330605","volume":"33","author":"CJ Vecht","year":"1993","unstructured":"Vecht CJ, Haaxma-Reiche H, Noordijk EM et al (1993) Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 33:583\u2013590. https:\/\/doi.org\/10.1002\/ana.410330605","journal-title":"Ann Neurol"},{"key":"10376_CR16","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(04)16250-8","volume":"363","author":"DW Andrews","year":"2004","unstructured":"Andrews DW, Scott CB, Sperduto PW et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363:1665\u20131672. https:\/\/doi.org\/10.1016\/S0140-6736(04)16250-8","journal-title":"Lancet"},{"key":"10376_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11060-009-0061-8","volume":"96","author":"SN Kalkanis","year":"2010","unstructured":"Kalkanis SN, Kondziolka D, Gaspar LE et al (2010) The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96:33\u201343. https:\/\/doi.org\/10.1007\/s11060-009-0061-8","journal-title":"J Neurooncol"},{"key":"10376_CR18","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1200\/JCO.19.02767","volume":"38","author":"PD Brown","year":"2020","unstructured":"Brown PD, Gondi V, Pugh S et al (2020) Hippocampal avoidance during Whole-Brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG oncology CC001. J Clin Oncol 38:1019\u20131029. https:\/\/doi.org\/10.1200\/JCO.19.02767","journal-title":"J Clin Oncol"},{"key":"10376_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1200\/JCO.2011.41.0639","volume":"31","author":"R Soffietti","year":"2013","unstructured":"Soffietti R, Kocher M, Abacioglu UM et al (2013) A European organisation for research and treatment of cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol 31:65\u201372. https:\/\/doi.org\/10.1200\/JCO.2011.41.0639","journal-title":"J Clin Oncol"},{"key":"10376_CR20","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1016\/j.wneu.2021.05.096","volume":"152","author":"A Michel","year":"2021","unstructured":"Michel A, Oppong MD, Rauschenbach L et al (2021) HER2 receptor conversion is a strong survival predictor in patients with breast cancer brain metastases. World Neurosurg 152:e332\u2013e343. https:\/\/doi.org\/10.1016\/j.wneu.2021.05.096","journal-title":"World Neurosurg"},{"key":"10376_CR21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/s0360-3016(99)00198-4","volume":"45","author":"D Kondziolka","year":"1999","unstructured":"Kondziolka D, Patel A, Lunsford LD et al (1999) Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 45:427\u2013434. https:\/\/doi.org\/10.1016\/s0360-3016(99)00198-4","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10376_CR22","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/annonc\/mdp407","volume":"21","author":"A Niwi\u0144ska","year":"2010","unstructured":"Niwi\u0144ska A, Murawska M, Pogoda K (2010) Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 21:942\u2013948. https:\/\/doi.org\/10.1093\/annonc\/mdp407","journal-title":"Ann Oncol"},{"key":"10376_CR23","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","volume":"32","author":"E Le Rhun","year":"2021","unstructured":"Le Rhun E, Guckenberger M, Smits M et al (2021) EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol 32:1332\u20131347. https:\/\/doi.org\/10.1016\/j.annonc.2021.07.016","journal-title":"Ann Oncol"},{"key":"10376_CR24","doi-asserted-by":"publisher","first-page":"R119","DOI":"10.1186\/bcr3244","volume":"14","author":"R Duchnowska","year":"2012","unstructured":"Duchnowska R, Dziadziuszko R, Trojanowski T et al (2012) Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain. Breast Cancer Res 14:R119. https:\/\/doi.org\/10.1186\/bcr3244","journal-title":"Breast Cancer Res"},{"key":"10376_CR25","doi-asserted-by":"publisher","unstructured":"Curtaz CJ, Kiesel L, Meybohm P et al (2022) Anti-Hormonal therapy in breast cancer and its effect on the Blood-Brain barrier. Cancers (Basel) 14. https:\/\/doi.org\/10.3390\/cancers14205132","DOI":"10.3390\/cancers14205132"},{"key":"10376_CR26","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA et al (2022) Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med 386:942\u2013950. https:\/\/doi.org\/10.1056\/NEJMoa2114663","journal-title":"N Engl J Med"},{"key":"10376_CR27","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M et al (2017) MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 35:3638\u20133646. https:\/\/doi.org\/10.1200\/JCO.2017.75.6155","journal-title":"J Clin Oncol"},{"key":"10376_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, Toi M, O\u2019Shaughnessy J et al (2023) Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a Preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 24:77\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(22)00694-5","journal-title":"Lancet Oncol"},{"key":"10376_CR29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.annonc.2021.12.005","volume":"33","author":"G Curigliano","year":"2022","unstructured":"Curigliano G, Mueller V, Borges V et al (2022) Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2\u2009+\u2009metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol 33:321\u2013329. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.005","journal-title":"Ann Oncol"},{"key":"10376_CR30","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim S-B, Chung W-P et al (2022) Trastuzumab Deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 386:1143\u20131154. https:\/\/doi.org\/10.1056\/NEJMoa2115022","journal-title":"N Engl J Med"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-025-10376-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-025-10376-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-025-10376-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T04:21:47Z","timestamp":1764562907000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-025-10376-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10376"],"URL":"https:\/\/doi.org\/10.1007\/s10585-025-10376-9","relation":{},"ISSN":["1573-7276"],"issn-type":[{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Ethics Committee of the University Medical Center of G\u00f6ttingen (approved 05\/17\/2024).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Due to the retrospective type of the study, an additional informed consent was not necessary.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"62"}}